Developments Tenax posts positive Phase 2 levosimendan data Tenax Therapeutics (NASDAQ:TENX) reported positive results from a Phase 2 trial evaluating levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH... June 4, 2020